In 992 patients, giredestrant plus palbociclib did not significantly improve investigator-assessed PFS versus letrozole plus ...

Early-phase clinical trials involving PIM-1 kinase inhibitors look promising. In the evolving landscape of myelofibrosis (MF) ...

IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.

Mezigdomide (a CELMoD) combined with carfilzomib/dexamethasone met the phase 3 primary endpoint, delivering statistically ...

Findings from a phase 1/2 trial (NCT04176) presented at the 2025 American Society of Hematology Annual Meeting and Exposition ...

Real-world community study finds Enhertu in HER2-low metastatic breast cancer has trial-like discontinuation rates; ILD remains key toxicity.

PATINA supports adding palbociclib to anti-HER2 plus endocrine therapy in HR+/HER2+ disease, and HER2CLIMB-05 validates tucatinib with HP after THP induction. Sequencing trials must address ADC ...

FDA grants priority review to T-DXd for high-risk HER2-positive early breast cancer with residual disease, after trial shows markedly better recurrence-free survival than T-DM1.

DNA MRD testing may spot hidden relapse and guide treatment holidays in metastatic gastroesophageal cancer, as deep ctDNA drops predict longer PFS. Posttreatment surveillance remains one of the most ...

Researchers launch a public immune atlas of pancreatic cancer therapy responses, allowing the public to rapidly link pancreatic cancer immunotherapy trials to immune shifts and outcomes. Imagine ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

CD25 rewires oncogene signaling in AML and ALL, revealing druggable complexes and a bold strategy: push pathways into toxic ...